MetaCap

Arcus Biosciences (RCUS) vs Xencor (XNCR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xencor (XNCR) has outperformed Arcus Biosciences (RCUS) over the past year, gaining 109.6% versus a loss of 29.2%. Over five years, XNCR leads with a -6.2% price change compared with -66.3% for RCUS. Xencor is the larger company by market cap ($2.50 billion vs $2.25 billion), about 1.1 times the size.

Xencor converts more of its revenue into profit, with a net margin of -73.2% versus -142.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RCUS-29.16%XNCR+109.58%
+161%+59%-44%
Nov 21, 20251 yearNov 20, 2026
RCUS-67.15%XNCR-9.77%
+15%-38%-90%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RCUS versus XNCR key metrics
MetricRCUSXNCR
Share price$15.62$33.26
Market cap$2.25B$2.50B
1-day change-1.01%-2.21%
YTD return-34.45%+117.24%
1-year return-29.16%+109.58%
5-year return-66.31%-6.15%
EPS (TTM)$-3.64$-1.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$247.00M$125.58M
Revenue growth (YoY)-4.26%+13.65%
Net income (latest FY)$-353.00M$-91.92M
Operating margin-156.28%-141.35%
Net margin-142.91%-73.20%
52-week high$31.74$40.60
52-week low$15.56$10.38
Distance from 52-week high-50.78%-18.08%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+162.48%+27.78%
Average volume1.85M1.54M
Shares outstanding143.99M75.04M
Employees601260
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XNCR has outperformed RCUS by 138.7 percentage points over the past year.
  • Xencor is more profitable, keeping -73.2 cents of every revenue dollar as net income versus -142.9 cents for Arcus Biosciences.
  • Xencor grew revenue faster in its latest fiscal year (+13.65% vs -4.26%).

About Arcus Biosciences

RCUS stock →

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees

About Xencor

XNCR stock →

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees

RCUS vs XNCR FAQ

Which is bigger, Arcus Biosciences or Xencor?

Xencor (XNCR) is larger, with a market capitalization of $2.50B compared with $2.25B for Arcus Biosciences (RCUS).

Which stock has performed better over the past year, RCUS or XNCR?

XNCR returned +109.58% over the past 12 months, compared with -29.16% for RCUS (price return, excluding dividends). Past performance does not predict future results.

Are Arcus Biosciences and Xencor in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons